A Col­orado biotech ends clin­i­cal work to fo­cus on mar­ket­ing AD­HD drug, con­sumer health prod­ucts

A bio­phar­ma that mar­kets an AD­HD med­ica­tion, and sells a port­fo­lio of over-the-counter con­sumer health prod­ucts on Ama­zon and else­where, has de­cid­ed to scrap all work on clin­i­cal-stage as­sets.

The En­gle­wood, CO-based biotech will do away with a glob­al Phase III tri­al that had be­gun just three months ago. The goal was to test en­za­s­tau­rin, or AR101, as a treat­ment for pa­tients with a cer­tain type of Vas­cu­lar Ehlers-Dan­los syn­drome, which can weak­en the aor­ta and oth­er ar­ter­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER